Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–2 of 2 stories
A new automated computational workflow named QUICHE has been developed to define structural characteristics of antitumor responses in triple-negative breast cancer. This advancement could enhance understanding of treatment responses in this aggressive cancer subtype.
Read full storyThe clinical trial landscape for triple-negative breast cancer (TNBC) is expanding with over 170 pipeline assets, including notable therapies like TECENTRIQ from Hoffmann La Roche and Leronlimab from CytoDyn. This growth is expected to significantly impact the TNBC treatment market.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.